Chronic pain presents a major health burden, affecting more than 20% of adults worldwide, but currently available analgesics lack efficacy and/or are associated with severe adverse effects. Here, Ellen Niederberger and colleagues discuss epigenetic modulation as a new opportunity in pain-relief therapy, and consider the future challenges for the clinical development of these drugs.
- Ellen Niederberger
- Eduard Resch
- Gerd Geisslinger
